Gene Therapy: The View from NCATS

Human Gene Therapy

Volumn 27, Issue 1, 2016, Pages 7-13

  Brooks, Philip J ^a   Yang, N Nora ^a   Austin, Christopher P ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; OLIGONUCLEOTIDE; PARVOVIRUS VECTOR; PLASMID DNA; RECOMBINANT DNA; TRANSCRIPTION ACTIVATOR LIKE EFFECTOR NUCLEASE; ZINC FINGER NUCLEASE;

ARTICLE; COMMERCIAL PHENOMENA; DUCHENNE MUSCULAR DYSTROPHY; EX VIVO GENE TRANSFER; GENE THERAPY; GIANT AXONAL NEUROPATHY; HUMAN; HYPERLIPOPROTEINEMIA TYPE 1; IMMUNE DEFICIENCY; MEDICAL RESEARCH; NONHUMAN; PARKINSON DISEASE; RARE DISEASE; RETROVIRIDAE; SPINAL MUSCULAR ATROPHY; TOXICITY TESTING; UREA CYCLE DISORDER; NATIONAL HEALTH ORGANIZATION; ORGANIZATION AND MANAGEMENT; TRANSLATIONAL RESEARCH; TRENDS; UNITED STATES;

GENETIC THERAPY; HUMANS; NATIONAL INSTITUTES OF HEALTH (U.S.); TRANSLATIONAL MEDICAL RESEARCH; UNITED STATES;

EID: 84955246583     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2016.29018.pjb     Document Type: Article

References (47)

1. Huang R, Southall N, Wang Y, et al. The NCGC pharmaceutical collection: A comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics. Sci Transl Med 2011;3:80ps16.
2. Brooks PJ, Tagle DA, Groft S. Expanding rare disease drug trials based on shared molecular etiology. Nat Biotechnol 2014;32:515-518.
3. O'Reilly M, Kohn DB, Bartlett J, et al. Gene therapy for rare diseases: summary of a National Institutes of Health workshop, September 13, 2012. Hum Gene Ther 2013;24:355-362.
4. Ainsztein AM, Brooks PJ, Dugan VG, et al. The NIH Extracellular RNA Communication Consortium. J Extracell Vesicles 2015;4:27493.
5. Alterman JF, Hall LM, Coles AH, et al. Hydrophobically modified siRNAs silence Huntingtin mRNA in primary neurons and mouse brain. Mol Ther Nucleic Acids 2015;4:e266.
6. Pusic AD, Kraig RP. Youth and environmental enrichment generate serum exosomes containing miR-219 that promote CNS myelination. Glia 2014;62:284-299.
7. Zhuang X, Teng Y, Samykutty A, et al. Grapefruitderived nanovectors delivering therapeutic miR17 through an intranasal route inhibit brain tumor progression. Mol Ther 2015. [Epub ahead of print]; doi: 10. 1038/mt. 2015. 188.
8. Dismuke DJ, Tenenbaum L, Samulski RJ. Biosafety of recombinant adeno-associated virus vectors. Curr Gene Ther 2013;13:434-452.
9. Nathwani AC, Tuddenham EG, Rangarajan S, et al. Adenovirus-associated virus vectormediated gene transfer in hemophilia B. N Engl J Med 2011;365:2357-2365.
10. Maguire AM, Simonelli F, Pierce EA, et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med 2008;358:2240-2248.
11. Amado D, Mingozzi F, Hui D, et al. Safety and efficacy of subretinal readministration of a viral vector in large animals to treat congenital blindness. Sci Transl Med 2010;2:21ra16.
12. Yla-Herttuala S. Endgame: Glybera finally recommended for approval as the first gene therapy drug in the European Union. Mol Ther 2012;20:1831-1832.
13. Foust KD, Nurre E, Montgomery CL, et al. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol 2009;27:59-65.
14. Foust KD, Wang X, McGovern VL, et al. Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nat Biotechnol 2010;28:271-274.
15. AveXis. Data from ongoing study of AVXS-101 in spinal muscular atrophy type 1 presented at World Muscle Congress. http://avexis. com/dataongoing-study-avxs-101-spinal-muscular-atrophytype-1-presented-world-muscle-congress/ (last accessed Dec. 14, 2015).
16. Gray SJ, Nagabhushan Kalburgi S, McCown TJ, et al. Global CNS gene delivery and evasion of anti-AAV-neutralizing antibodies by intrathecal AAV administration in non-human primates. Gene Ther 2013;20:450-459.
17. Flotte TR. The role of patient advocacy organizations in advancing human gene therapy. Hum Gene Ther 2015;26:782.
18. Aiuti A, Slavin S, Aker M, et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 2002;296:2410-2413.
19. Gaspar HB, Cooray S, Gilmour KC, et al. Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction. Sci Transl Med 2011;3:97ra80.
20. Candotti F, Shaw KL, Muul L, et al. Gene therapy for adenosine deaminase-deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans. Blood 2012;120:3635-3646.
21. Verma IM. Medicine. Gene therapy that works. Science 2013;341:853-855.
22. Aiuti A, Biasco L, Scaramuzza S, et al. Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science 2013;341:1233151.
23. Biffi A, Montini E, Lorioli L, et al. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science 2013;341:1233158.
24. Biffi A, Aubourg P, Cartier N. Gene therapy for leukodystrophies. Hum Mol Genet 2011;20:R42-R53.
25. Katz ML, Tecedor L, Chen Y, et al. AAV gene transfer delays disease onset in a TPP1-deficient canine model of the late infantile form of Batten disease. Sci Transl Med 2015;7:313ra180.
26. Beaudet AL, Meng L. Gene-targeting pharmaceuticals for single gene disorders. Hum Mol Genet 2015. [Epub ahead of print]
27. Rajeev KG, Nair JK, Jayaraman M, et al. Hepatocyte-specific delivery of siRNAs conjugated to novel non-nucleosidic trivalent Nacetylgalactosamine elicits robust gene silencing in vivo. Chembiochem 2015;16:903-908.
28. Kormann MS, Hasenpusch G, Aneja MK, et al. Expression of therapeutic proteins after delivery of chemically modified mRNA in mice. Nat Biotechnol 2011;29:154-157.
29. Kariko K, Buckstein M, Ni H, et al. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 2005;23:165-175.
30. Basner-Tschakarjan E, Mingozzi F. Cell-mediated immunity to AAV vectors, evolving concepts and potential solutions. Front Immunol 2014;5:350.
31. Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 2002;20:709-760.
32. Mayrhofer P, Schleef M, Jechlinger W. Use of minicircle plasmids for gene therapy. Methods Mol Biol 2009;542:87-104.
33. Li L, Dimitriadis EK, Yang Y, et al. Production and characterization of novel recombinant adenoassociated virus replicative-form genomes: A eukaryotic source of DNA for gene transfer. PLoS One 2013;8:e69879.
34. Kornbrust D, Cavagnaro J, Levin A, et al. Oligo safety working group exaggerated pharmacology subcommittee consensus document. Nucleic Acid Ther 2013;23:21-28.
35. Savic N, Schwank G. Advances in therapeutic CRISPR/Cas9 genome editing. Transl Res 2015. [Epub ahead of print]; doi: 10. 1016/j. Trsl. 2015. 09. 008.
36. Kim H, Kim JS. A guide to genome engineering with programmable nucleases. Nat Rev Genet 2014;15:321-334.
37. LaFountaine JS, Fathe K, Smyth HD. Delivery and therapeutic applications of gene editing technologies ZFNs, TALENs, and CRISPR/Cas9. Int J Pharm 2015;494:180-194.
38. Frock RL, Hu J, Meyers RM, et al. Genome-wide detection of DNA double-stranded breaks induced by engineered nucleases. Nat Biotechnol 2015;33:179-186.
39. Tebas P, Stein D, Tang WW, et al. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med 2014;370:901-910.
40. Wang J, Exline CM, DeClercq JJ, et al. Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat Biotechnol 2015;33:1256-1263.
41. Yin H, Xue W, Chen S, et al. Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nat Biotechnol 2014;32:551-553.
42. Ran FA, Cong L, Yan WX, et al. In vivo genome editing using Staphylococcus aureus Cas9. Nature 2015;520:186-198.
43. Long C, Amoasii L, Mireault AA, et al. Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy. Science 2015. [Epub ahead of print]
44. Tabebordbar M, Zhu K, Cheng JK, et al. In vivo gene editing in dystrophic mouse muscle and muscle stem cells. Science 2015. [Epub ahead of print]; DOI: 10. 1126/science. aad5177.
45. Nelson CE, Hakim CH, Ousterout DG, et al. In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. Science 2015. [Epub ahead of print]; DOI: 10. 1126/ science. aad5143.
46. Sharma R, Anguela XM, Doyon Y, et al. In vivo genome editing of the albumin locus as a platform for protein replacement therapy. Blood 2015;126:1777-1784.
47. Orthwein A, Noordermeer SM, Wilson MD, et al. A mechanism for the suppression of homologous recombination in G1 cells. Nature 2015;528:422-426.